Condition
Healthy Volunteers
Hepatic Steatosis
Locations
United Kingdom
Start date
12/03/2025
Identifiers
Trial ID
NN6581-4981,
NCT number NCT06891365,
Eudract number Not Available
NCT number NCT06891365,
Eudract number Not Available
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of NNC0581-0001 in participants with hepatic steatosis and suspected steatohepatitis (increased liver fat and suspected inflammation). NNC0581-0001 will be given in 2 different dose levels as injection under the skin (once per month for 3 months). Participants will either get NNC0581-001 or Placebo (dummy treatment). Which treatment participants get is decided by chance. NNC0581-0001 is a new medicine which cannot be prescribed by doctors. The study will last about 58 weeks.
Trial Overview:
Treatment
DRUG: NNC0581-0001
DRUG: Placebo (NNC0581-0001)
Study type
INTERVENTIONAL
Trial duration
Mar 12 2025 - Jan 25 2027
Participants
48
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 64 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.